The Modern DMTA Cycle: Why MedChem Works Better When Biology, CADD and DMPK Share the Same Clock

The design–make–test–analyze (DMTA) cycle is the core engine of small molecule drug discovery, but it delivers value only when all components move in sync and data is interpreted collectively. When design is delayed by late DMPK insights, biology outputs lack mechanistic context, or chemistry outpaces data understanding, programs risk being active without gaining insights.

A modern DMTA cycle synchronizes medicinal chemistry, computational chemistry, assay biology, DMPK, analytics and pharmacology. The objective is not merely to turn the crank. It is to make each cycle more informative than the last.

Design should integrate multiple data streams

The design stage should begin with a shared review of the most important data. Which analogues improved potency? Which harmed permeability? Where did metabolic instability appear? Did structural biology confirm the binding pose? Did cellular potency track with biochemical potency? Did a safety signal emerge? Which compounds were hard to synthesize or purify?

When CADD, medicinal chemistry, assay biology, and DMPK evaluate these insights together, the next compound set becomes more targeted, enabling hypothesis-driven design rather than broad, unguided exploration.

Make should be fast but purposeful

Synthetic speed creates value only when aligned with the design intent. Parallel synthesis, library synthesis, scaffold and building-block access, route creativity and analytical support can accelerate compound delivery. However, chemistry teams must avoid generating large numbers of analogues that do not answer the program’s key questions.

Jubilant Biosys supports medicinal chemistry, synthetic chemistry, analytical chemistry and specialized chemistry capabilities across heterocycles, asymmetric chemistry, carbohydrates, nucleosides, nucleotides, peptides, lipids, PROTACs and oligonucleotide synthesis. This breadth helps teams choose chemistry that matches the program need.

Test and analyze should not be separated

Testing should generate interpretable, decision ready data. Potency must be assessed in context of assay conditions, compound quality, solubility, DMPK, permeability, clearance, and structural hypotheses. A less potent compound may still be valuable if it improves exposure or mitigates safety risks, while a highly potent molecule may be unsuitable if it lacks developability.

The analyze stage is critical in the DMTA cycle, where teams interpret outcomes. It should clearly identify which hypotheses hold, which fail, and define the next set of hypotheses to test, ensuring each cycle drives smarter decisions.

Shared cadence creates decision velocity

Coordinated execution across DMTA reduces cycle lag. DMPK automation and high throughput ADME can provide feedback at a cadence aligned with chemistry needs, while assay biology can integrate primary and orthogonal assays to build reliable SAR. CADD continuously refines models with emerging data, and medicinal chemistry prioritizes compounds that address key hypotheses.
When all disciplines operate on a synchronized timeline, programs learn faster—yielding not just more compounds, but a clearer path to candidates with balanced potency, pharmacokinetics, safety, and developability.

Speak with Jubilant Biosys about synchronized DMTA execution across chemistry, biology, CADD and DMPK.

Protein Quality Is Program Quality: Gene-to-Structure Strategies for Better Discovery Decisions

High-quality protein is one of the most important foundations in drug discovery. It affects assay performance, screening reliability, biophysical measurements, crystallography and structure-based design. Poor protein quality can create false negatives, false positives, irreproducible data and misleading SAR. Protein sciences therefore influence the entire discovery trajectory. 

For many targets, obtaining suitable protein is not straightforward. Construct boundaries, expression system, solubility, post-translational modifications, cofactors, complexes, purification method and storage conditions can all determine whether the protein is fit for purpose. 

Gene-to-protein strategy should match the end use 

A protein intended for a biochemical assay may need different characteristics from one intended for crystallography, SPR or fragment screening. Assay protein must be active and stable under assay conditions. SPR protein may require specific immobilization or tagging strategies. Crystallography may require construct engineering, truncations, mutations, complex formation or removal of flexible regions. 

Jubilant Biosys provides protein expression and purification services across E. coli, baculo-insect and mammalian systems, along with construct design, expression optimization, scale-up, co-expression, protein complexes, refolding, chromatography purification and protein QC. These capabilities support biochemical and biophysical assays, high-throughput screening and structural studies. 

Quality control prevents downstream ambiguity

Protein QC should not be minimal. Purity, identity, intact mass, aggregation state, activity, stability, buffer compatibility and post-translational modifications can all affect the outcome of downstream experiments. Thermal shift assays, mass spectrometry, SDS-PAGE, Western blotting, size exclusion chromatography and biophysical analysis help define whether the protein is suitable for its intended use. 

If a screen produces low hit rates or inconsistent data, the problem may be protein quality rather than chemical matter. If a structure cannot be solved, construct design or crystallization strategy may need revision. If SPR binding appears nonspecific, immobilization or protein behavior may be responsible. 

Protein sciences strengthen integrated discovery

Protein science is most valuable when connected to assay biology, CADD, medicinal chemistry and structural biology. A protein construct that supports both assay development and crystallography can accelerate the transition from hit finding to structure-based optimization. Protein QC data can explain assay variability. Structural insights can guide medicinal chemistry. SPR kinetics can add mechanistic understanding to potency values. 

At Jubilant Biosys, protein sciences and crystallography can be integrated with computational chemistry, medicinal chemistry, assay biology and DMPK. This creates a faster path from target reagent to validated hit and structure-informed lead optimization. 

Better reagents create better decisions 

In discovery, teams often focus on compounds. But the quality of the target reagent is equally important. Reliable protein enables reliable assays, reliable binding data and reliable structures. That reliability reduces wasted chemistry cycles and strengthens confidence in the program. 

A disciplined gene-to-structure strategy helps ensure that the biology the team is testing is real, reproducible and actionable. For challenging targets, that foundation can determine whether the program moves forward or stalls. 

Talk to Jubilant Biosys about protein production and structural biology support for your discovery program.